Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

14.66 6.77

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.73

Max

14.71

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-4.3M -18M
Pelnas, tenkantis vienai akcijai	-0.19
Darbuotojai	37
EBITDA	-5.3M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+129.99% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	32M 1.2B
Ankstesnė atidarymo kaina	7.89
Ankstesnė uždarymo kaina	14.66

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-11 23:56; UTC

Coherent Corp shares are higher in after-market trading, continuing a strong upward trend since Tuesday's close amid broader market volatility and fluctuating oil prices.

2026-08-11 23:56; UTC

Paychex Inc. shares are higher in after-market trading, maintaining a position above its 20-day moving average amid recent volatility in Brent crude oil prices.

2026-08-11 23:56; UTC

Arcos Dorados Holdings shares are higher in after-market trading, despite five consecutive lower sessions. Market volatility is influenced by rising Brent crude oil prices.

2026-08-11 23:56; UTC

Citizens Financial Group Inc shares are higher in after-hours trading, remaining above their 20-day moving average and near the upper end of their one-month range.

2026-08-11 23:56; UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

2026-08-11 23:56; UTC

Assurant Inc. shares rose after-market, recovering from an early dip amid broader market volatility linked to Brent crude oil fluctuations and investor caution ahead of CPI data.

2026-08-11 23:56; UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

2026-08-11 23:56; UTC

Macy's Inc. shares are higher in after-market hours, driven by notable strength in the Broadline Retail sub-sector, despite no specific company news identified.

2026-08-11 23:56; UTC

Monro Inc shares are trading higher in after-market hours amid broader market volatility and rising Brent crude oil prices above $90 per barrel.

2026-08-11 23:56; UTC

Social Media

Twilio Inc shares are higher in after-market hours, supported by social media discussions on a "massive stage 1 base breakout" and increased full-year guidance.

2026-08-11 23:56; UTC

Kaiser Aluminum Corp shares are higher in after-market trading. The stock remains above its 20-day moving average amid broader market volatility.

2026-08-11 23:56; UTC

Alibaba Group Holding Ltd shares are higher in after-market trading, reflecting routine performance within a narrow range above the 20-day moving average.

2026-08-11 23:56; UTC

CH Robinson Worldwide shares are trading higher in after-market hours, reflecting some resilience amid broader market volatility and fluctuating Brent crude oil prices.

2026-08-11 23:56; UTC

Fluence Energy Inc shares are higher in after-market hours, trading within a narrow range. No specific news was identified to explain the movement.

2026-08-11 23:56; UTC

Chemours Co shares are higher in after-market trading, reflecting notable activity since Tuesday's close. The stock remains below its 20-day moving average.

2026-08-11 23:56; UTC

Genco Shipping & Trading Ltd shares are higher in after-market trading, rising from session lows despite being below its 20-day moving average and near a one-month low.

2026-08-11 23:56; UTC

Broadridge Financial Solutions Inc shares are higher in after-market trading, recovering from a session dip and remaining above the 20-day moving average.

2026-08-11 23:56; UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

2026-08-11 23:56; UTC

Kraft Heinz Co shares are trading slightly higher in after-market hours. No specific news was identified to explain this movement.

2026-08-11 23:56; UTC

PennyMac Mortgage Investment Trust shares are higher in after-market trading, reflecting a slight uptick amid broader market volatility. No specific news was identified.

2026-08-11 23:56; UTC

Correlated Moves

American Water Works Company reported no specific news after-market hours. The stock was roughly flat, reflecting broader market sentiment and stability.

2026-08-11 23:56; UTC

Atmos Energy Corp shares are trading higher in after-market hours. This movement occurs amid broader market volatility and fluctuating Brent crude oil prices.

2026-08-11 23:56; UTC

Axon Enterprise Inc. shares are lower in after-market trading, despite a recent trend of three consecutive higher daily closes.

2026-08-11 23:52; UTC

ETF Constituents

Correlated Moves

Macro News

iShares MSCI South Korea ETF rises in after-market trading, supported by technology stock gains and broader equity market movements. It remains above its 20-day moving average.

2026-08-11 23:52; UTC

Monster Beverage Corp. shares rose during after-market hours, recovering from a slight pullback. Market focus remains on upcoming economic data, including the CPI report.

2026-08-11 23:52; UTC

Social Media

Entravision Communications Corp shares are rising in after-market trading amid positive investor sentiment and discussions of potential favorable price movements.

2026-08-11 23:52; UTC

Correlated Moves

Booking Holdings Inc shares are lower in after-market hours amid broader market declines. Investors await the upcoming consumer price index report for further guidance.

2026-08-11 23:51; UTC

Xpeng Inc. shares were roughly flat in after-market trading. Market attention remains on the upcoming consumer price index report amid recent job loss data.

2026-08-11 23:51; UTC

Correlated Moves

Cohu Inc. shares are lower in after-market trading, influenced by a slight decline in the Nasdaq 100 Index and overall market sentiment.

2026-08-11 23:51; UTC

Eton Pharmaceuticals Inc shares are lower in after-market trading amid unusual volatility. No specific news was identified to explain the decline.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

129.99% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 129.99%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.